Advancing new therapeutic options for pulmonary arterial hypertension
CoTherix was a biopharmaceutical company focused on licensing, developing, and commercializing therapeutics for cardiovascular diseases. The company licensed and developed Ventavis (iloprost), an inhaled prostacyclin analgoue for the treatment of pulmonary arterial hypertension that was approved by the FDA in 2004. Cotherix completed its IPO on NASDAQ in 2004 and was acquired by Actelion in 2006.
